Dianthus Therapeutics, Inc. /DE/
DNTHNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | — | — | — |
| Operating income | −$177.9M | −$101.9M | −$48.2M | −$29.7M | −$74.7M | −$78.7M |
| Net income | −$162.3M | −$85.0M | −$43.6M | −$28.5M | −$71.1M | −$74.9M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M | $161.6M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M | $17.7M |
| Equity | $493.4M | $352.5M | $168.9M | −$44.4M | $172.7M | $143.9M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 | $-1.71 |
| Shares out. | 32.1M | 29.3M | 60.6M | 58.8M | 48.6M | 39.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −8739.3%
- Net margin
- −7973.3%
- Return on equity
- −32.9%
- Return on assets
- −30.6%
- Return on capital (ROCE)
- −35.6%
- Liabilities / assets
- 7.1%
- Debt / equity
- 0.08×
- Book value / share
- $15.36
- Revenue growth (YoY)
- −67.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 14.17safe
- Accruals / assets
- −6.3%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Ra Capital Management, L.P.Passive (13G)May 15, 2026
- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Sirenia Capital Management LpPassive (13G)May 15, 2026
- Wellington Management Group LlpPassive (13G)May 15, 2026
- Octagon Capital Advisors LpPassive (13G)May 14, 2026
- Blackrock, Inc.Passive (13G)Apr 27, 2026
- Fairmount Funds Management LlcActivist (13D)Nov 25, 2025
- Avidity Partners Management LpActivist (13D)Nov 19, 2025
- Bcls Fund Iii Investments, LpPassive (13G)Nov 14, 2025
- Deep Track Capital, LpPassive (13G)Nov 14, 2025
- Vestal Point Capital, LpPassive (13G)Nov 14, 2025
- Fmr LlcPassive (13G)Nov 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Soteropoulos PaulaDirector | May 8, 2026 | Option exercise | 599 | $8.44 |
| Savitz RyanOfficer — EVP, CFO & CBO | Apr 9, 2026 | Option exercise | 8,224 | $17.88 |
| Savitz RyanOfficer — EVP, CFO & CBO | Mar 31, 2026 | Option exercise | 74,367 | $8.44 |
| Soteropoulos PaulaDirector | Mar 31, 2026 | Option exercise | 599 | $8.44 |
| Soteropoulos PaulaDirector | Mar 24, 2026 | Option exercise | 27,594 | $8.44 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.4M | 14.3 | -1.9% |
| Apr 30, 2026 | 6.6M | 14.1 | -0.2% |
| Apr 15, 2026 | 6.6M | 8.3 | -27.6% |
| Mar 31, 2026 | 9.1M | 7.4 | -1.4% |
| Mar 13, 2026 | 9.2M | 4.8 | +16.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 22, 2026
- Results of operationsMay 5, 2026
- Other material eventMar 26, 2026
- Entered a material agreementMar 12, 2026
- Results of operations · Regulation FD disclosure · Other material eventMar 9, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Results of operationsNov 5, 2025
- Other material eventNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 144Jun 1, 2026
- 4May 22, 2026
- 4May 22, 2026
- 4May 22, 2026
- 4May 22, 2026
- 4May 22, 2026
- 4May 22, 2026
- 4May 22, 2026
- 8-KMay 22, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 14, 2026
- 4May 11, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.